ImmunityBio Accounts Payable

ImmunityBio (IBRX) currently reports a accounts payable of $11M as of March 2026. That compares with $14M in the prior-year period — down 17.1% year over year. Use the charts on this page to explore ImmunityBio's accounts payable history and peer comparisons.

ImmunityBio's accounts payable decreased from $14M to $11M — a 17.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunityBio reported $11M in accounts payable as of March 2026. That compares with $14M in the prior-year period — down 17.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.

ImmunityBio is classified in the Healthcare sector. On accounts payable, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBRX with unrelated industries.